Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 13/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099706 | 0.90 | P2RY12 (0.66) | P2RY12KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL4118941 | 0.89 | P2RY12 (0.56) | P2RY12KDM4E | |
| SCHEMBL4110667 | 0.85 | P2RY12 (0.61) | P2RY12CYP3A4CYP2C9 | |
| SCHEMBL4103151 | 0.83 | P2RY12 (0.57) | P2RY12KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL4105701 | 0.83 | P2RY12 (0.54) | P2RY12KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL4104025 | 0.82 | P2RY12 (0.82) | P2RY12CYP3A4CYP2C9 | |
| SCHEMBL4112806 | 0.81 | P2RY12 (0.42) | P2RY12 | |
| SCHEMBL4878088 | 0.80 | P2RY12 (0.69) | P2RY12CYP3A4CYP2C9 | |
| SCHEMBL4104931 | 0.77 | P2RY12 (0.52) | P2RY12KDM4EKMT2AMEN1 | |
| SCHEMBL4112559 | 0.76 | P2RY12 (1.00) | P2RY12CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885KDM4E 3376/4885ALDH1A1 1820/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | P2RY12 1/4885KDM4E 2316/4885ALDH1A1 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.